FOXR2, also known as FOXN6, was firstly identified at RP11167p23, containing a highly conserved forkhead domain at its C-terminus .
FOXR2 was identified as a direct and functional target of miR-202.
Mutant 3-UTR of FOXR2  was generated using QuikChange site-directed mutagenesis kit (Stratagene, Cedar Creek, TX, USA).
The slides were then blocked with goat serum and incubated with FOXR2 primary antibody.
Chi-square (v2) and Fisher's exact test were used to measure the relationship between the miR-202 and FOXR2 expression.
miR-202 Downregulates FOXR2 by Directly Targeting Its 3-UTR.
FOXR2 Is Upregulated in EAC and Is Associated with Poor Prognosis.
FOXR2 is a member of the FOX protein family and plays important roles in the development and progression of cancers.
Li, "Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer," Biomedicine & Pharmacotherapy, vol.
Li, "FOXR2 contributes to cell proliferation and malignancy in human hepatocellular carcinoma," Tumour Biology, vol.
Huang, "High expression of FOXR2 in breast cancer correlates with poor prognosis," Tumour Biology, vol.
Lyons et al., "Identification of FoxR2 as an oncogene in medulloblastoma," Cancer Research, vol.